Key result
Perindopril lowers BP without altering serum lipids or apolipoproteins versus placebo.
Why the study?
Does perindopril alter serum lipids and apolipoprotein concentrations in hyperlipidemic patients with mild hypertension?
RCT (n=51)
double-blind
randomized
Yes
Does perindopril alter serum lipids and apolipoprotein concentrations in hyperlipidemic patients with mild hypertension?
Perindopril effectively lowers blood pressure in patients with mild hypertension without adversely affecting lipid profiles, making it a suitable antihypertensive for patients with concomitant hyperlipidemia.
Answers are grounded in this paper and cite their sources.
Supports perindopril in mild hypertension with hyperlipidemia; confirms neutral lipid and apolipoprotein effects.
The effect of the angiotensin-converting enzyme (ACE)-inhibitor perindopril on serum lipids and apolipoprotein concentrations were assessed in a multicenter, randomized, double-blind, placebo-controlled study in 51 hyperlipidemic patients treated for mild hypertension. Perindopril was given as a single morning dose (4 mg) for 6 weeks. During the treatment period, blood pressure (BP) was significantly (p < 0.001) reduced from 159/99 to 148/90 mm Hg by verum treatment and from 158/101 to 151/95 mm Hg (NS) by placebo treatment. Neither total cholesterol and triglycerides nor high-density-lipoprotein and apolipoprotein AI and B levels were significantly altered by drug treatment as compared with placebo. Although perindopril had good antihypertensive effect in patients with mild hypertension and hyperlipidemia, it had no adverse effects on lipid metabolism in these patients. Therefore, perindopril is recommended for antihypertensive treatment, especially in hypertensive patients with concomitant hyperlipidemia.
No takes yet. Share an insight, caveat, or question.
Middeke et al. (1994) conducted an RCT in mild hypertension and hyperlipidemia (n=51). Perindopril vs. placebo was evaluated on Serum lipids and apolipoprotein concentrations. Perindopril reduced blood pressure from 159/99 to 148/90 mm Hg without altering serum lipid or apolipoprotein levels compared with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: